WO2022071233A1 - 優れた保存効力を示す液状医薬組成物 - Google Patents
優れた保存効力を示す液状医薬組成物 Download PDFInfo
- Publication number
- WO2022071233A1 WO2022071233A1 PCT/JP2021/035417 JP2021035417W WO2022071233A1 WO 2022071233 A1 WO2022071233 A1 WO 2022071233A1 JP 2021035417 W JP2021035417 W JP 2021035417W WO 2022071233 A1 WO2022071233 A1 WO 2022071233A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- present
- salt
- compound
- benzyl alcohol
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 63
- 238000004321 preservation Methods 0.000 title abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 202
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 144
- 150000003839 salts Chemical class 0.000 claims abstract description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 48
- 150000001875 compounds Chemical class 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 32
- 150000001720 carbohydrates Chemical class 0.000 claims description 24
- 239000003002 pH adjusting agent Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 11
- 230000002335 preservative effect Effects 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- TUWCZRFHNIOVTC-UHFFFAOYSA-N fuzapladib Chemical compound CCS(=O)(=O)NC1=NC=C(C(F)(F)F)C=C1NC(=O)C1CCCCC1 TUWCZRFHNIOVTC-UHFFFAOYSA-N 0.000 abstract description 16
- 238000012360 testing method Methods 0.000 description 44
- 230000000844 anti-bacterial effect Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 238000003860 storage Methods 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 18
- 229940125904 compound 1 Drugs 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- -1 alkali metal salt Chemical class 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 206010033645 Pancreatitis Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 229960000281 trometamol Drugs 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 241001331781 Aspergillus brasiliensis Species 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ABXYOVCSAGTJAC-JGWLITMVSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-JGWLITMVSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- OKPQBUWBBBNTOV-UHFFFAOYSA-N Kojibiose Natural products COC1OC(O)C(OC2OC(OC)C(O)C(O)C2O)C(O)C1O OKPQBUWBBBNTOV-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- QACUPNAKIPYZAW-RMQWDSPGSA-N O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QACUPNAKIPYZAW-RMQWDSPGSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- PZDOWFGHCNHPQD-OQPGPFOOSA-N kojibiose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-OQPGPFOOSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- QIGJYVCQYDKYDW-LCOYTZNXSA-N laminarabiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-LCOYTZNXSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- the present invention relates to a liquid composition containing N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof, which exhibits excellent preservative efficacy.
- N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof has a phospholipase A2 inhibitory effect and is useful as an active ingredient of an anti-inflammatory agent or an antipancreatitis agent.
- Patent Document 1 N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof has a phospholipase A2 inhibitory effect and is useful as an active ingredient of an anti-inflammatory agent or an antipancreatitis agent.
- Patent Documents 1 to 5 describe a pharmaceutical composition such as an injection containing the above-mentioned active ingredient, and in that case, an antibacterial agent such as benzyl alcohol may be contained. Is also described.
- Benzyl alcohol is an antibacterial agent widely used in injections and the like, but the optimum condition for its antibacterial activity is less than pH 5, and when it exceeds pH 8, there is almost no antibacterial activity (Non-Patent Document 1).
- Non-Patent Document 1 N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof is hardly soluble in water having a pH of 5 or less.
- N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof may be added to a composition such as an injection, particularly a multi-use vial. It is desired to use it as a filled composition for a long period of time. Therefore, there is still a need for the development of technical means for enhancing the preservative potency of liquid compositions comprising N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or salts thereof. ..
- N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof and benzyl alcohol unexpectedly has antibacterial activity.
- N- (2-Ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide (Fuzaprazib) is represented by the structural formula of the following formula (1), and is hereinafter represented by the formula (1). Sometimes abbreviated as compound.
- an object of the present invention is to provide a liquid composition containing N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof having enhanced storage efficacy.
- the present invention includes the following inventions.
- the compound of formula (1) or a salt thereof A liquid composition containing benzyl alcohol and water.
- the composition according to [1] further comprising a saccharide and, if desired, a pH adjuster.
- the saccharide is at least one selected from the group consisting of monosaccharides, disaccharides, polysaccharides and sugar alcohols.
- the pH adjuster is a buffer.
- the composition according to any one of [1] to [4], wherein the content of benzyl alcohol in the liquid composition is 0.9 to 3 w / v%.
- a kit for producing the composition according to any one of [1] to [7]. A kit comprising a first composition comprising a compound of formula (1) or a salt thereof and a second composition comprising benzyl alcohol and water.
- the first composition comprises a saccharide and optionally a pH regulator.
- a first composition comprising the compound of formula (1) or a salt thereof
- a production method comprising the step of mixing a second composition comprising benzyl alcohol and water.
- the method comprising setting the pH of the liquid composition to 8 or more.
- the preservation effect in a liquid composition containing the compound of the formula (1) or a salt thereof can be effectively enhanced. Therefore, the composition of the present invention is advantageous in that it can be used as a composition for multiple doses, for example, a composition filled in a multi-use vial.
- the liquid composition of the present invention contains benzyl alcohol together with N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof and water, and has a pH of 8 or more. It has one feature.
- N- (2-Ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof The N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide in the present invention is described above. It is represented by the structural formula of the formula (1).
- the salt of the compound of the formula (1) may be any pharmaceutically acceptable salt, for example, an alkali metal salt such as a potassium salt or a sodium salt, an alkaline earth metal salt such as a calcium salt, or triethanol. Examples thereof include amine salts and organic amine salts such as tris (hydroxymethyl) aminomethane salts.
- the salt of the compound of the formula (1) may be one having water of crystallization among these salts, that is, a hydrate.
- the compound of the formula (1) or a salt thereof can be produced, for example, by the method described in JP-A-06-263735.
- the content of the compound of the formula (1) or a salt thereof in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention, but is, for example, 0 with respect to the entire composition. .001 to 15 w / v (mass / volume)%, preferably 0.005 to 10 w / v%, more preferably 0.01 to 5 w / v%, still more preferably 0.01 to 1 w / v%. , More preferably 0.1 to 1 w / v%.
- the content of the compound of formula (1) or a salt thereof in the composition of the present invention can be measured by the HPLC method, for example, according to the method described in Example 1 of International Publication No. 2019/167799.
- Benzyl alcohol in the present invention, benzyl alcohol can be used to confer a preservative effect.
- the content of benzyl alcohol in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention.
- the lower limit of the content of benzyl alcohol is, for example, 0.8 w / v% or more, preferably 0.9 w / v% or more, and more preferably 1.2 w / v% or more.
- the upper limit of the content of benzyl alcohol is, for example, 5 w / v% or less, preferably 4 w / v% or less, more preferably 3 w / v% or less, and further preferably 2 w / v% or less. be.
- 0.9 to 5 w / v% is mentioned, preferably 0.9 to 4 w / v%, more preferably 0.9 to 3 w / v%, and even more preferably 1. It is 2 to 2 w / v%.
- the content of benzyl alcohol in the composition of the present invention can be measured, for example, by the HPLC method, but it can also be measured by other methods commonly used in the art.
- the mass ratio of the compound of the formula (1) or a salt thereof to benzyl alcohol [the compound of the formula (1) or a salt thereof: the mass ratio of benzyl alcohol].
- Water used in the present invention is not particularly limited, and includes water used as a medicine or food, or used in the future.
- purified water ion-exchanged water, distilled water, ultra-filtered water, ultrapure water (for example, milliQ water), injection water, physiological saline and the like can be mentioned, and injection water is preferable.
- the composition may further contain saccharides.
- saccharides are not particularly limited, and include those used as pharmaceuticals or foods, or those used in the future.
- the saccharide of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention, and examples thereof include monosaccharides, disaccharides, polysaccharides, sugar alcohols, and combinations thereof, and monosaccharides, disaccharides, and sugars are preferable. It is an alcohol, more preferably a sugar alcohol.
- Examples of the monosaccharide include glucose (dextrose), galactose, mannose, fructose (fructose), psicose, allose, sorbose, arabinose, galactosamine, glucosamine, xylose, thioglucose, deoxyribose, fucose, and combinations thereof, which are preferable.
- disaccharide examples include lactose (lactose), sucrose, maltose (maltose), isomaltose, nigerose, kojibiose, trehalose, genthiobiose, cellobiose, sophorose, nigerose, palatinose, melibiose, laminaribiose, and combinations thereof. Lactose (lactose) is preferable.
- polysaccharide examples include dextrin, glycogen, starch, modified starch, and combinations thereof, and dextrin and starch are preferable.
- sugar alcohol examples include mannitol, sorbitol, inositol, xylitol, magnesium gluconate, maltitol, meglumine, and combinations thereof, preferably mannitol, and more preferably D-mannitol.
- the saccharide of the present invention is preferably a water-soluble saccharide.
- the "water-soluble” of saccharides that can be used in the present invention is a property that belongs to “extremely soluble", “easily soluble”, “slightly soluble” or “slightly insoluble” according to the general rules of the 17th revised Japanese Pharmacopoeia. Is.
- the saccharide of the present invention has, for example, a solubility in water of about 10 mg / mL or more, preferably about 33 mg / mL or more, more preferably 100 mg / mL at a normal handling temperature, for example, around room temperature of 20 ° C. That is all.
- the content of saccharides in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention, but is, for example, 0.01 to 20 w / v% with respect to the entire composition. It is preferably 0.1 to 10 w / v%, and more preferably 1 to 3 w / v%.
- the composition may further contain a pH regulator.
- the pH adjuster is not particularly limited, and includes those used as pharmaceuticals or foods, or those used in the future.
- Examples of the pH adjuster in the present specification include compounds suitable for adjusting the pH of the liquid composition to 8 or more, for example, the pH described later (for example, pH 8 to 11).
- the pH regulator may include a buffer.
- the buffering agent may be a buffering substance or a buffer solution for adjusting the pH changed by an acid or a base to a desired pH. Therefore, the pH adjuster contained in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention, and examples thereof include acids, bases, and buffers.
- Examples of the acid include organic acids and inorganic acids.
- Specific acids include, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, maleic acid, acetic acid, citric acid, tartrate acid, propionic acid, succinic acid, oxalic acid, lactic acid, malic acid, glutamic acid, pamoic acid, and Examples thereof include hydrochloric acid, phosphoric acid, acetic acid, and citric acid.
- Examples of the base include organic bases and inorganic bases.
- Specific bases include sodium hydroxide, potassium hydroxide, ammonia, tromethamine (tris), and combinations thereof, with preference given to sodium hydroxide and tromethamine (tris).
- the buffer is not particularly limited as long as it does not interfere with the effects of the present invention, but is not limited to acetate, lactate, tartrate, citrate, succinate, histidine hydrochloride, phosphate (eg, potassium phosphate, etc.).
- Organic acid salts such as sodium phosphate), citrate buffer (eg, sodium citrate buffer, etc.), Tris buffer (eg, Tris hydrochloride buffer, etc.), histidine buffer, imidazole buffer, carbonate buffer, etc.
- Aqueous buffers known in the field of solution formulations such as triethanolamine buffers, as well as combinations thereof.
- the concentration of the acid or base in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention, but is preferably 0.001 to 2 w / v%, for example. Is 0.01 to 1.5 w / v%, more preferably 0.1 to 1 w / v%.
- the concentration of the buffer solution in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention, but is, for example, 1 to 500 mM, preferably 5 to 200 mM. , More preferably 10 to 100 mM.
- the composition of the present invention contains, if necessary, a pharmaceutically acceptable additive.
- the pharmaceutically acceptable additive is not particularly limited, but is an aqueous medium, a solvent, a base, a solubilizing agent, an tonicity agent, a stabilizer, an adjusting agent, a chelating agent, an excipient, and a thickener.
- Colorants, antioxidants, dispersants, emulsifiers, solubilizers and the like can be blended within a range that does not impair the effects of the present invention.
- the shape of the composition of the present invention is liquid.
- the composition of the present invention contains a compound of the formula (1) or a salt thereof, benzyl alcohol and water, but the dosage form is not particularly limited as long as the characteristics of the combination are retained, and the injection is not limited. It can be provided as a drip agent, a syrup agent, an enema agent, or the like.
- the dosage form is preferably an injection or a drip.
- the injection comprises a product in which the composition of the present invention is filled in a vial or a syringe.
- the vial include a single-use vial and a multi-use vial, and a multi-use vial is preferable.
- the plurality of times includes, for example, 2 to 20 times, preferably 3 to 18 times. When a vial used multiple times is used, it is preferable that the preservation effect of the composition of the present invention is maintained even after puncturing.
- the composition of the present invention may be a composition for single dose or multiple doses, preferably a composition for multiple doses.
- a composition for multiple doses examples include a composition filled in a vial, and preferably a composition filled in a multi-use vial.
- the plurality of times is the number of times as described above.
- the pH of the composition of the present invention is 8 or more, preferably 8 to 11, and more preferably 8 to 10 from the viewpoint of improving the solubility of the compound of the formula (1) or a salt thereof. Further, the pH of the composition of the present invention is not particularly limited with respect to the time of measurement thereof, and may be at the time of preparation, storage or use of the composition. The pH of the composition can be measured using a commercially available pH meter (for example, LAQUA F-74, manufactured by HORIBA, Ltd.).
- the composition of the present invention is known such that the compound of the formula (1) or a salt thereof, water and benzyl alcohol are mixed, if necessary, with another solvent or the like. It can be manufactured by the method of. Further, since the composition of the present invention may further contain a saccharide and, if desired, a pH adjuster, the compound of formula (1) or a salt thereof, water, benzyl alcohol, a saccharide and, if desired, a pH adjuster and / or others. It can be produced by a known method such as mixing the solvents of the above.
- the composition of the present invention can be produced by a known method such as mixing and dissolving the compound of the formula (1) or a salt thereof, water, benzyl alcohol, and if necessary, another solvent or the like. More specifically, as a method for producing the composition of the present invention, the compound of the formula (A) or a salt thereof, benzyl alcohol, a saccharide and a pH adjuster are mixed, and then water is added (. B) Mix water, benzyl alcohol, saccharides and a pH regulator, then add the compound of formula (1) or a salt thereof, (C) Mix water with benzyl alcohol and a compound of formula (1) or a salt thereof. Then, a method such as adding a saccharide and a pH adjuster can be mentioned. Further, in the production of the composition of the present invention, the above mixture may be homogenized or sterilized as long as the effects of the present invention are not impaired.
- the other solvent used for producing the composition of the present invention is not particularly limited, and includes those used as pharmaceuticals or foods, or those used in the future.
- Specific examples of the other solvent include alcohols (eg, methanol, ethanol, propanol, propylene glycol, etc.), organic acids (eg, acetic acid, propionic acid, etc.), polyethylene glycol, and a mixed solvent thereof. ..
- the composition of the present invention can effectively enhance the preservative efficacy of a liquid composition comprising the compound of the formula (1) of the present invention or a salt thereof. can.
- Such storage efficacy is USP (eg, USP43-NF38-S2), European Pharmacopoeia (eg, Ph.Eur. 10.4) and Japanese Pharmacopoeia (eg, 17th revised Japanese Pharmacopoeia, 18th revised Japanese Pharmacopoeia). It is preferable that it conforms to at least one standard specified in (1).
- the bacterium having a viable cell count of 105 to 106 per 1 ml or 1 g of the liquid composition of the present invention is, for example, 10 2 to 10 3 after 24 hours. It is represented by the number or less, preferably 10 1 to 10 2 or less, more preferably 10 1 or less.
- the storage efficacy of the liquid composition of the present invention is as follows: 10 5 to 10 6 viable fungi per 1 ml or 1 g of the present invention, for example, 10 3 to 10 4 after 7 days. Or less, preferably 10 2 to 10 3 or less, more preferably 10 1 or less.
- the subject exhibiting the above-mentioned preservative effect is not particularly limited, and examples thereof include bacteria and / or fungi.
- examples of the bacterium include Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus
- examples of the fungus include Candida albicans and Aspergillus brasiliensis.
- the composition of the present invention in which the compound of the formula (1) or a salt thereof and benzyl alcohol coexist is continuously provided for a long period of time by enhancing the storage efficacy.
- the composition of the present invention can be used discontinuously.
- the composition of the present invention can be used, for example, for 1 day or longer, preferably 7 days or longer, more preferably 14 days or longer, still more preferably 21 days or longer, still more preferably 28 days or longer.
- the upper limit is not particularly limited, but 40 days or less is preferable.
- Kit According to another aspect of the present invention, a kit for producing the composition of the present invention described above, the first composition containing the compound of formula (1) or a salt thereof, and benzyl alcohol.
- a kit comprising a second composition comprising water and water is provided.
- the first composition comprises a saccharide and, if desired, a pH adjuster.
- the first composition may contain a pharmaceutically acceptable additive, if necessary.
- the sugars, pH regulators and pharmaceutically acceptable additives are as described above.
- the first composition is preferably freeze-dried.
- the first composition is filled in a vial.
- vials include single-use vials and multi-use vials, preferably multi-use vials.
- the plurality of times includes, for example, 2 to 20 times, preferably 3 to 18 times. When a vial used multiple times is used, it is preferable that the preservation effect of the composition of the present invention is maintained even after puncturing.
- the content of benzyl alcohol in the second composition is, for example, 0.9 to the whole of the second composition or the whole composition of the present invention.
- 5 w / v% is mentioned, preferably 0.9 to 4 w / v%, more preferably 0.9 to 3 w / v%, still more preferably 1.2 to 2 w / v%.
- the above-mentioned production method may be a method of reconstitution of the first composition containing the compound of the formula (1) or a salt thereof with the second composition, benzyl alcohol and water.
- the first composition can be produced by a known method such as mixing and dissolving the compound of the formula (1) or a salt thereof and a solvent.
- the first composition is preferably lyophilized.
- the first composition may contain a saccharide and a pH adjuster if desired, the compound of formula (1) or a salt thereof, a saccharide and a pH adjuster if desired, and a solvent (eg, water and / or). It can be produced by a known method such as mixing with another solvent) and dissolving it.
- the first composition can be produced by a known method such as mixing and dissolving the compound of the formula (1) or a salt thereof, a saccharide and a pH adjuster in water and / or other solvents and the like. More specifically, as a method for producing the first composition, (A) a compound of formula (1) or a salt thereof, a saccharide and a pH adjuster are mixed, and then water is added, (B) water. And the saccharide and the pH adjuster are mixed, then the compound of formula (1) or a salt thereof is added, (C) water is mixed with the compound of formula (1) or a salt thereof, and then the saccharide and the pH adjuster are added. Examples include the addition of. Then, if necessary, the solution obtained by the above method can be freeze-dried. Further, in the production of the first composition, the first composition may be homogenized or sterilized as long as the effects of the present invention are not impaired.
- the other solvent used for producing the first composition is the same as the other solvent used for producing the composition of the present invention.
- the second composition can be produced by a known method such as mixing benzyl alcohol and water. Further, in the production of the second composition, the second composition may be homogenized or sterilized as long as the effects of the present invention are not impaired.
- the composition of the invention or the first composition is an inflammatory cell (eg, granulocytes (neutrophils, eosinophils, basal spheres), lymphocytes (eg, eg). Diseases, pathologies, or symptoms associated with (T lymphocytes, NK cells), monospheres, macrophages, plasma cells, obese cells, platelets (eg, pancreatitis, surgical invasion, disseminated intravascular coagulation syndrome (DIC), neoplastic Disease, uterine pyorrhea, heat stroke, immune-mediated hemolytic anemia (IMHA), sepsis, angiosarcoma, gastric torsion, ischemia-reperfusion injury, purpura, liver failure, hepatitis, pneumonia, systemic inflammatory response syndrome (SIRS), Trauma, osteoarthritis, cystitis, disc disease, atopy / allergy, dermatitis, immune-mediated disease, ear inflammation, inflammatory bowel disease, chronic
- inflammatory cell e
- the composition of the present invention or the first composition can exert a therapeutic and preventive action against pancreatitis, surgical invasion, disseminated intravascular coagulation (DIC) and the like.
- the composition or first composition of the invention is a disease, condition, or condition associated with inflammatory cells, preferably pancreatitis, surgical invasion, or disseminated. It is provided as a composition for the treatment or prevention of intravascular coagulation syndrome (DIC).
- DIC intravascular coagulation syndrome
- the composition of the present invention or the first composition can also be used as a pharmaceutical product or quasi-drug for humans or animals.
- the composition of the present invention or the first composition may be appropriately used in combination with other pharmaceutical products and quasi-drugs commonly used in the present technical field, if necessary.
- the object to which the composition of the present invention is applied includes, for example, animals, preferably non-human animals such as mammals, birds, reptiles, amphibians, and fish. Preferred are mice, rats, rabbits, dogs, cats, pigs, cows and horses.
- the animal may be a domestic animal, a pet, a domestic animal, a wild animal, or a competitive animal.
- the subject may be a healthy person (healthy animal) or a patient (patient animal).
- the composition of the present invention is a composition for multiple doses, for example, when the composition of the present invention is filled in a vial for multiple use, the target of the multiple doses is the same individual. May also be different individuals (ie, multiple individuals).
- a disease, condition, or symptom associated with the subject's inflammatory cells preferably pancreatitis, surgery, comprising administering to the subject the composition of the invention.
- Methods for treating or preventing invasive or disseminated intravascular coagulation (DIC) are provided.
- the above-mentioned method for treating or preventing a disease, pathological condition, or symptom associated with an inflammatory cell of a subject is non-therapeutic except for medical practice when the subject is a healthy person. It is said to be a standard method.
- a method for treating or preventing a disease, pathological condition, or symptom related to an inflammatory cell of the present invention can be carried out for the composition of the present invention according to the contents described in the present specification.
- the effective amount of the compound of the formula (1) or a salt thereof and the number of administrations of the composition of the present invention are not particularly limited, and the type, purity and composition of the compound of the formula (1) or a salt thereof are not particularly limited. It is appropriately determined by those skilled in the art according to the dosage form, the type of the subject, the nature, the sex, the age, the symptoms and the like.
- the effective amount of the compound of the formula (1) or a salt thereof is 0.01 to 1000 mg / kg body weight, preferably 0.05 to 500 mg / kg body weight.
- the number of administrations is, for example, 1 to 5 times a day, preferably 1 to 3 times a day, and more preferably 1 to 2 times a day in the same individual.
- the administration period is, for example, 1 to 7 days, preferably 1 to 5 days, and more preferably 1 to 3 days in the same individual.
- the compound of the formula (1) or a salt thereof, benzyl alcohol and water are used in combination, and the pH of the liquid composition is 8.
- the composition comprises a disease, condition, or condition associated with inflammatory cells, preferably pancreatitis, surgical invasion, or disseminated intravascular coagulation (DIC). Used for the treatment or prevention of.
- the use of the compound of the formula (1) or a salt thereof in combination with benzyl alcohol is provided for enhancing the storage efficacy in a liquid composition having a pH of 8 or higher.
- the treatment or prevention of a disease, condition, or condition associated with inflammatory cells preferably pancreatitis, surgical invasion, or disseminated intravascular coagulation (DIC). The use of the above combinations for is provided.
- a compound of the formula (1) or a combination thereof and a benzyl alcohol for enhancing the storage efficacy in a liquid composition having a pH of 8 or higher.
- the treatment or prevention of a disease, condition, or condition associated with inflammatory cells preferably pancreatitis, surgical invasion, or disseminated intravascular coagulation (DIC).
- DIC disseminated intravascular coagulation
- it is a method for enhancing the preservative effect of a liquid composition containing the compound of the formula (1) or a salt thereof, wherein the compound of the formula (1) or a salt thereof and benzyl are used.
- the preservation effect is preferably a preservation effect against bacteria and / or fungi.
- -Compound 1 N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide-monosodium salt-monohydrate (Fuzaprazib sodium hydrate) -D-mannitol: manufactured by Nacalai Tesque Co., Ltd. (Test Examples 1 and 2) and Roquette Freres (Test Examples 3 and 4).
- -Trometamin manufactured by Nacalai Tesque Co., Ltd. (Test Examples 1 and 2), Biospectra, Inc. Made (Test Examples 3 and 4)
- Benzyl alcohol Spectrum Chemical Manufacturing Crop. Made by Lanxess Germany (Test Examples 1 and 2), manufactured by Lanxess Germany GmbH (Test Examples 3 and 4)
- the equipment used in the test examples is as follows.
- -Magnetic stirrer Pasolina mini stirrer CT-1AT, AS ONE Corporation (Test Examples 1 and 2)
- -High Shear Mixer BX-60, manufactured by Silverson (Test Examples 3 and 4)
- -PH meter LAQUA F-74, manufactured by HORIBA, Ltd.
- -Sterilization filter DISMIC-25AS, manufactured by ADVANTEC (Test Examples 1 and 2), KA2EKVP1G, Pall Manufacturing Ltd. Made (Test Examples 3 and 4)
- Test Example 1 Examination of antibacterial properties of compound 1-containing liquid composition (1)
- test groups 1 to 4 One or more of compound 1, D-mannitol, tromethamine and benzyl alcohol are placed in a 20 mL screw cap bottle, weighed, 15 mL of water for injection is added, and a magnetic stirrer is added. Was mixed and dissolved by. Then, 0.1 M HCl or 0.1 M NaOH was added to adjust the pH to the pH shown in Table 1. The obtained solution was transferred to a 20 mL volumetric flask, and the total volume was adjusted to 20 mL with water for injection, and then mixed so as to be uniform. The liquid composition of the test group shown in Table 1 was obtained through a sterilization filter.
- (B) Evaluation of antibacterial property of the liquid composition containing compound 1 The evaluation of antibacterial property was carried out with reference to the preservation efficacy test (EFFICACY OF ANTIMICROBIAL PRESSERVATION) of EUROPEAN PHARMACOEIA 9.0. Specifically, the procedure was as follows. A stock solution of Escherichia coli (hereinafter, also referred to as E. coli) was prepared using Luria Bertani medium (viable cell count 4.08 ⁇ 10 7 per 1 mL of E. coli stock solution). Then, with respect to 500 ⁇ L of the liquid composition prepared in (a), E.I. 5 ⁇ L of the coli stock solution was inoculated and mixed. The cells were stored at 20 to 25 ° C. under shading, and the viable cell count after 24 hours was measured. The viable cell count 0 hours after inoculation was determined by adding E. coli to physiological saline. The viable cell count immediately after inoculation with the colli stock solution and mixing was used.
- Test Example 2 Examination of antibacterial properties of compound 1-containing liquid composition (2)
- (A) Preparation of liquid composition (test group 5 to 10) One or more of compound 1, D-mannitol, tromethamine and benzyl alcohol are weighed in a 20 mL screw cap bottle, 15 mL of water for injection is added, and a magnetic stirrer is used. It was mixed and dissolved. Then, 0.1 M HCl or 0.1 M NaOH was added to adjust the pH to the pH shown in Table 2. The obtained solution was transferred to a 20 mL volumetric flask, and the total volume was adjusted to 20 mL with water for injection, and then mixed so as to be uniform. The liquid composition of the test group shown in Table 2 was obtained through a sterilization filter.
- test group 5 With benzyl alcohol alone, the antibacterial efficacy shown at pH 4.9 (test group 5) is hardly shown at pH 8.7 (test group 6), and compound 1 alone (test group 7) also shows antibacterial activity at pH 8.7. It had little effect. However, when benzyl alcohol and compound 1 were mixed (test group 8), the viable cell count 24 hours after inoculation became 0 at pH 8.7, and the antibacterial efficacy was significantly enhanced.
- Test Example 3 Examination of antibacterial properties of compound 1-containing liquid composition (3)
- (A) Preparation of lyophilized preparation Compound 1 (160 g), D-mannitol (600 g), tromethamine (240 g) and water (17 kg) were mixed. After adjusting the pH to 8.7 with 1M hydrochloric acid, water was added to make a total volume of 20 L. The obtained mixture was sterilized by filtration through a 0.2 ⁇ m filter, 1.75 mL was placed in a vial, the rubber stopper was half-plugged, and then lyophilized. After lyophilization, the rubber stopper was completely tapped and wrapped with an aluminum seal to obtain a lyophilized preparation.
- Vials were removed on days 2 and 3, and the vial was punctured once with a syringe equipped with a 20 gauge needle to remove approximately 0.05 mL of drug solution. The vial was then stored at room temperature for a predetermined period of time.
- (D) pH measurement and antibacterial property evaluation of the liquid composition containing compound 1 The pH was measured immediately after the reconstruction, and the pH was measured and the antibacterial property was evaluated on the 8th day. The pH was measured by the glass electrode method. The antibacterial properties were evaluated by USP43-NF38-S2 General Chapter ⁇ 51> and Ph. Eur. 10.4 General Chapter 5.1.3 was performed according to the storage efficacy test.
- the test bacteria used in this test example were Staphylococcus aureus (S.
- test bacteria As Candida albicans (C. albicans) and Aspergillus brasiliensis (A. brasiliensis).
- the test bacteria were inoculated into the liquid composition prepared and stored in (b), mixed and incubated at 20-25 ° C.
- the number of colonies formed (CFU / mL) after 0 hours, 6 hours, 24 hours, 7 days, 14 days and 28 days of inoculation was measured.
- the number of inoculum was set to be between 1 ⁇ 10 5 to 1 ⁇ 10 6 colony forming numbers (CFU / mL) in the suspension after inoculation.
- the evaluation criteria are the USP acceptance criteria for injections and other parenteral agents and the parenteral preparation Ph. Eur. Based on pass / fail criteria.
- Test results 1 PH of liquid composition The pH of the liquid composition was 8.7 immediately after the reconstitution and 8.7 after storage for 8 days.
- Test Example 4 Examination of antibacterial properties of compound 1-containing liquid composition (4)
- A Preparation of lyophilized preparation
- Compound 1 160 g
- D-mannitol 600 g
- tromethamine 240 g
- water 17.7
- water was added to make a total volume of 20 L.
- the obtained mixture was sterilized by filtration through a 0.2 ⁇ m filter, 1.75 mL was placed in a vial, the rubber stopper was half-plugged, and then lyophilized. After lyophilization, the rubber stopper was completely tapped and wrapped with an aluminum seal to obtain a lyophilized preparation.
- test bacteria used in this test example were Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and Escherichia coli (E. coli) as bacteria.
- Candida albicans C. albicans
- Aspergillus brasiliensis A. brasiliensis
- the test bacteria were inoculated into the liquid composition prepared and stored in (b) and mixed. Incubated at 20 to 25 ° C., the number of colonies formed (CFU / mL) after 0 hours, 6 hours, 24 hours, 7 days, 14 days and 28 days of inoculation was measured. The number of inoculum was determined after inoculation. The number of colonies formed in the suspension was 1 ⁇ 10 5 to 1 ⁇ 10 6 (CFU / mL).
- the evaluation criteria were based on the same pass / fail criteria as in Test Example 3.
- Test results 1 PH of liquid composition The pH of the liquid composition was 8.7 immediately after the reconstitution and 8.7 after storage for 29 days.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
[1] 式(1)の化合物またはその塩:
ベンジルアルコールと
水と
を含んでなる液状組成物であって、
pHが8以上である
組成物。
[2] 糖類および所望によりpH調整剤をさらに含んでなる、[1]に記載の組成物。
[3] 前記糖類が、単糖、二糖、多糖および糖アルコールからなる群から選択される少なくとも1種である、[2]に記載の組成物。
[4] 前記pH調整剤が、緩衝剤である、[2]に記載の組成物。
[5] 液状組成物中のベンジルアルコールの含量が、0.9~3w/v%である、[1]~[4]のいずれか一つに記載の組成物。
[6] 液状組成物中の式(1)の化合物またはその塩の含量が、0.01~1w/v%である、[1]~[5]のいずれか一つに記載の組成物。
[7] 複数回投与のための、[1]~[6]のいずれか一つに記載の組成物。
[8] [1]~[7]のいずれか一つに記載の組成物を製造するためのキットであって、
式(1)の化合物またはその塩を含んでなる第1の組成物と
ベンジルアルコールと水とを含んでなる第2の組成物と
を含んでなる、キット。
[9] 第1の組成物が、糖類および所望によりpH調整剤を含んでなる、[8]に記載のキット。
[10] 第2の組成物中のベンジルアルコールの含量が、第2の組成物に対して、0.9~3w/v%である、[8]または[9]に記載のキット。
[11] 第1の組成物が、バイアルに充填されている、[8]~[10]のいずれか一つに記載のキット。
[12] バイアルが、単回使用バイアルまたは複数回使用バイアルである、[11]に記載のキット。
[13] バイアルが、複数回使用バイアルである、[12]に記載のキット。
[14] [1]~[7]のいずれか一つに記載の組成物の製造方法であって、
式(1)の化合物またはその塩を含んでなる第1の組成物と、
ベンジルアルコールと水とを含んでなる第2の組成物と
を混合する工程を含む、製造方法。
[15] 式(1)の化合物またはその塩を含んでなる液状組成物の保存効力を増強させる方法であって、式(1)の化合物またはその塩とベンジルアルコールとを液状組成物中に共存させ、液状組成物のpHを8以上とすることを含んでなる、方法。
本発明におけるN-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドは上記式(1)の構造式で表される。
式(1)の化合物の塩としては、薬学的に許容される塩であればよく、例えば、カリウム塩、ナトリウム塩のようなアルカリ金属塩、カルシウム塩のようなアルカリ土類金属塩、トリエタノールアミン塩、トリス(ヒドロキシメチル)アミノメタン塩のような有機アミン塩等が挙げられる。さらに、式(1)の化合物の塩は、これら塩の中で結晶水をもつもの、すなわち、水和物であってもよい。
式(1)の化合物またはその塩は、例えば、特開平06-263735号公報に記載の方法により製造することができる。
本発明において、ベンジルアルコールは保存効力を付与するために使用することができる。
本発明において使用される水としては、特に限定されるものではなく、医薬品あるいは食品として使用され、または将来使用されるものが含まれる。例えば、精製水、イオン交換水、蒸留水、超ろ過水、超純水(例えば、ミリQ水)、注射用水、生理食塩水等が挙げられ、好ましくは、注射用水である。
本発明の一実施態様によれば、上記組成物はさらに糖類を含んでもよい。かかる糖類としては、特に限定されるものではなく、医薬品あるいは食品として使用され、または将来使用されるものが含まれる。
本発明の一実施態様によれば、上記組成物はさらにpH調整剤を含んでもよい。かかるpH調整剤としては、特に限定されるものではなく、医薬品あるいは食品として使用され、または将来使用されるものが含まれる。
本発明の一つの実施態様によれば、本発明の組成物は、本発明の式(1)の化合物またはその塩を含んでなる液状組成物の保存効力を効果的に増強することができる。かかる保存効力は、USP(例えば、USP43-NF38-S2)、European Pharmacopoeia(例えば、Ph.Eur.10.4)および日本薬局方(例えば、第十七改正日本薬局方、第十八改正日本薬局方)に規定された少なくとも一つの基準に適合していることが好ましい。具体的な保存効力としては、対象が細菌である場合、本発明の液状組成物1mlまたは1gあたり105~106個の生菌数の細菌が、24時間後に、例えば、102~103個またはそれ以下、好ましくは101~102個またはそれ以下、より好ましくは101個またはそれ以下に減少することにより表される。また、対象が真菌である場合の保存効力としては、本発明の液状組成物1mlまたは1gあたり105~106個の生菌数の真菌が、7日後に、例えば、103~104個またはそれ以下、好ましくは102~103個またはそれ以下、より好ましくは101個またはそれ以下に減少することにより表される。上記保存効力試験は、USP43-NF38-S2 General Chapter<51>またはPh.Eur.10.4 General Chapter 5.1.3の保存効力試験に準じて実施でき、例えば、試験例1、3および4と同様の条件で実施される。
本発明の別の態様によれば、上記で説明した本発明の組成物を製造するためのキットであって、式(1)の化合物またはその塩を含む第1の組成物と、ベンジルアルコールと水とを含む第2の組成物とを含んでなる、キットが提供される。
・化合物1:N-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミド・一ナトリウム塩・一水和物(フザプラジブナトリウム水和物)
・D-マンニトール:ナカライテスク株式会社製(試験例1,2)、Roquette Freres社製(試験例3,4)
・トロメタミン:ナカライテスク株式会社製(試験例1,2)、Biospectra,Inc.製(試験例3,4)
・ベンジルアルコール:Spectrum Chemical Manufacturing Crop.社製(試験例1,2)、Lanxess Deutschland GmbH製(試験例3,4)
・マグネティックスターラー:パソリナミニスターラー CT-1AT、アズワン株式会社(試験例1,2)
・High Shear Mixer:BX-60、Silverson社製(試験例3,4)
・pHメーター:LAQUA F-74、株式会社堀場製作所製
・滅菌フィルター:DISMIC-25AS、ADVANTEC社製(試験例1,2)、KA2EKVP1G、Pall Manufacturing Ltd.製(試験例3,4)
(a)液状組成物(試験区1~4)の調製
化合物1、D-マンニトール、トロメタミンおよびベンジルアルコールのうち、ひとつまたは複数を20mLねじ口瓶に入れ秤量し、注射用水15mLを加え、マグネティックスターラーによって混合溶解した。その後、0.1M HClまたは0.1M NaOHを添加して表1のpHに調整した。得られた溶液を20mLメスフラスコに移し、注射用水にて全量20mLとした後、均一となるように混合した。滅菌フィルターを通して、表1に記載の試験区の液状組成物を得た。
(b)化合物1含有液状組成物の抗菌性評価
抗菌性の評価はEUROPEAN PHARMACOEIA 9.0 の保存効力試験(EFFICACY OF ANTIMICROBIAL PRESERVATION)を参考として行った。具体的には、以下の通り行った。Luria Bertani培地を用いて大腸菌(Escherichia coli)(以下、E.coliともいう)原液を調製した(E.coli原液1mLあたり生菌数4.08×107個)。その後、(a)で作製した液状組成物500μLに対してE.coli原液5μLを接種し、混合した。遮光下20~25℃に保存し、24時間後の生菌数を測定した。なお、菌接種0時間後の生菌数は、生理食塩水にE.coli原液を接種し、混合した直後の生菌数とした。
(a)液状組成物(試験区5~10)の調製
化合物1、D-マンニトール、トロメタミンおよびベンジルアルコールのうち、ひとつまたは複数を20mLねじ口瓶に秤量し、注射用水15mLを加え、マグネティックスターラーによって混合溶解した。その後、0.1M HClまたは0.1M NaOHを添加して表2のpHに調整した。得られた溶液を20mLメスフラスコに移し、注射用水にて全量20mLとした後、均一となるように混合した。滅菌フィルターを通して、表2に記載の試験区の液状組成物を得た。
(b)化合物1含有液状組成物の抗菌性評価
抗菌性の評価はEUROPEAN PHARMACOEIA 9.0 の保存効力試験を参考とした。具体的には、以下の通り行った。試験例1と同様に、E.coli原液を調製した(E.coli原液1mLあたり生菌数9.90×107個)。その後、(a)で作製した液状組成物500μLに対してE.coli原液5μLを接種し、混合した。遮光下20~25℃に保存し、24時間後の生菌数を測定した。なお、菌接種0時間後の生菌数は、生理食塩水にE.coli原液を接種し、混合した直後の生菌数とした。
(a)凍結乾燥製剤の調製
化合物1(160g)、D-マンニトール(600g)、トロメタミン(240g)および水(17kg)を混合した。1M塩酸にてpH8.7に調整後、水を加えて全量20Lとした。得られた混合物を、0.2μmのフィルターで濾過滅菌し、1.75mLをバイアルに入れ、ゴム栓を半打栓後、凍結乾燥した。凍結乾燥後、ゴム栓を全打栓し、アルミシールで巻き締めをして、凍結乾燥製剤を得た。
(b)液状組成物の調製
(a)で得られたバイアルに、20ゲージ針を備えたシリンジを用いて1.8w/v%のベンジルアルコール含有注射用水(3.5mL)を入れて、凍結乾燥製剤を再構成し、液状組成物を得た。
(c)液状組成物の保管
各バイアルを、20ゲージ針を備えたシリンジで穿刺し、それぞれ約0.05mLの薬液を取り出した。穿刺毎にシリンジを取り換えて2回繰り返した後、バイアルを室温で保管した。2日目および3日目にバイアルを取り出し、20ゲージ針を備えたシリンジでバイアルを1回穿刺し、約0.05mLの薬液を取り出した。その後バイアルを室温で所定期間保管した。
(d)化合物1含有液状組成物のpH測定および抗菌性評価
再構成直後にpHの測定、8日目にpHの測定および抗菌性の評価を行った。
pHの測定はガラス電極法にて行った。
抗菌性の評価はUSP43-NF38-S2 General Chapter<51>およびPh.Eur.10.4 General Chapter 5.1.3の保存効力試験に従って行った。本試験例で使用した試験菌は、細菌として黄色ブドウ球菌(Staphylococcus aureus(S.aureus))、緑膿菌(Pseudomonas aeruginosa(P.aeruginosa))および大腸菌(Esherichia Coli(E.coli))、真菌としてカンジダ・アルビカンス(Candida albicans(C.albicans))およびアスペルギス・ブラジリエンシス(Aspergillus brasiliensis(A.brasiliensis))である。試験菌を(b)で作製および保管した液状組成物に接種し、混合し、20~25℃でインキュベートした。接種0時間、6時間、24時間、7日、14日及び28日経過後のコロニー形成数(CFU/mL)を測定した。なお、植菌数は、接種後の懸濁液中1×105~1×106コロニー形成数(CFU/mL)の間となるようにした。評価基準は、下記表に示す、注射、その他の非経口剤USP合格基準および非経口製剤Ph.Eur.合否基準に基づいた。
1.液状組成物のpH
液状組成物のpHは、再構成直後:8.7、8日間保管後:8.7であった。
結果を下記表に示す。下記の表に示す通り、本液状組成物は、注射、その他の非経口剤USP合格基準および非経口製剤Ph.Eur.合否基準に適合した。
(a)凍結乾燥製剤の調製
化合物1(160g)、D-マンニトール(600g)、トロメタミン(240g)および水(17kg)を混合した。1M塩酸にてpH8.7に調整後、水を加えて全量20Lとした。得られた混合物を、0.2μmのフィルターで濾過滅菌し、1.75mLをバイアルに入れ、ゴム栓を半打栓後、凍結乾燥した。凍結乾燥後、ゴム栓を全打栓し、アルミシールで巻き締めをして、凍結乾燥製剤を得た。
(b)液状組成物の調製
(a)で得られたバイアルに、20ゲージ針を備えたシリンジを用いて1.8w/v%のベンジルアルコール含有注射用水(3.5mL)を入れて、凍結乾燥製剤を再構成し、液状組成物を得た。
(c)液状組成物の保管
各バイアルを、20ゲージ針を備えたシリンジで穿刺し、それぞれ約0.05mLの薬液を取り出した。穿刺毎にシリンジを取り換えて2回繰り返した後、バイアルを冷蔵庫(2~8℃)で保管した。2日目から13日目まで、1日1回バイアルを冷蔵庫から取り出し、20ゲージ針を備えたシリンジでバイアルを穿刺し、約0.05mLの薬液を取り出した。その後バイアルを冷蔵庫で所定期間保管した。
(d)化合物1含有液状組成物のpH測定および抗菌性評価
再構成直後にpHの測定、29日目にバイアルを冷蔵庫から取り出し、pHの測定並びに抗菌性の評価を行った。pHの測定はガラス電極法にて行った。抗菌性の評価はUSP43-NF38-S2 General Chapter<51>およびPh.Eur.10.4 General Chapter 5.1.3の保存効力試験に従って行った。本試験例で使用した試験菌は、細菌として黄色ブドウ球菌(Staphylococcus aureus(S.aureus))、緑膿菌(Pseudomonas aeruginosa(P.aeruginosa)および大腸菌(Esherichia Coli(E.coli))、真菌としてカンジダ・アルビカンス(Candida albicans(C.albicans))およびアスペルギス・ブラジリエンシス(Aspergillus brasiliensis(A.brasiliensis))である。試験菌を(b)で作製および保管した液状組成物に接種し、混合し、20~25℃でインキュベートした。接種0時間、6時間、24時間、7日、14日及び28日経過後のコロニー形成数(CFU/mL)を測定した。なお、植菌数は、接種後の懸濁液中1×105~1×106コロニー形成数(CFU/mL)とした。評価基準は、試験例3と同様の合否基準に基づいた。
1.液状組成物のpH
液状組成物のpHは、再構成直後:8.7、29日間保管後:8.7であった。
結果を下記表に示す。下記の表に示す通り、本液状組成物は、注射、その他の非経口剤USP合格基準および非経口製剤Ph.Eur.合否基準に適合した。
Claims (14)
- 糖類および所望によりpH調整剤をさらに含んでなる、請求項1に記載の組成物。
- 前記糖類が、単糖、二糖、多糖および糖アルコールからなる群から選択される少なくとも1種である、請求項2に記載の組成物。
- 前記pH調整剤が、緩衝剤である、請求項2に記載の組成物。
- 液状組成物中のベンジルアルコールの含量が、0.9~3w/v%である、請求項1~4のいずれか一項に記載の組成物。
- 液状組成物中の式(1)の化合物またはその塩の含量が、0.01~1w/v%である、請求項1~5のいずれか一項に記載の組成物。
- 複数回投与のための、請求項1~6のいずれか一項に記載の組成物。
- 請求項1~7のいずれか一項に記載の組成物を製造するためのキットであって、
式(1)の化合物またはその塩を含んでなる第1の組成物と
ベンジルアルコールと水とを含んでなる第2の組成物と
を含んでなる、キット。 - 第1の組成物が、糖類および所望によりpH調整剤を含んでなる、請求項8に記載のキット。
- 第2の組成物中のベンジルアルコールの含量が、第2の組成物に対して、0.9~3w/v%である、請求項8または9に記載のキット。
- 第1の組成物が、バイアルに充填されている、請求項8~10のいずれか一項に記載のキット。
- 前記バイアルが、単回使用バイアルまたは複数回使用バイアルである、請求項11に記載のキット。
- 請求項1~7のいずれか一項に記載の組成物の製造方法であって、
式(1)の化合物またはその塩を含んでなる第1の組成物と、
ベンジルアルコールと水とを含んでなる第2の組成物と
を混合する工程を含む、製造方法。 - 式(1)の化合物またはその塩を含んでなる液状組成物の保存効力を増強させる方法であって、式(1)の化合物またはその塩とベンジルアルコールとを液状組成物中に共存させ、液状組成物のpHを8以上とすることを含んでなる、方法。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3194011A CA3194011A1 (en) | 2020-09-29 | 2021-09-27 | Liquid-state pharmaceutical composition exhibiting excellent preservative effectiveness |
KR1020237014639A KR20230084205A (ko) | 2020-09-29 | 2021-09-27 | 우수한 보존 효력을 나타내는 액상 의약 조성물 |
US18/246,775 US20230372315A1 (en) | 2020-09-29 | 2021-09-27 | Liquid-State Pharmaceutical Composition Exhibiting Excellent Preservative Effectiveness |
PE2023001208A PE20240109A1 (es) | 2020-09-29 | 2021-09-27 | Composicion farmaceutica en estado liquido que exhibe excelente eficacia conservante |
CN202180066887.2A CN116472032A (zh) | 2020-09-29 | 2021-09-27 | 显示优异防腐效力的液态医药组合物 |
JP2022553959A JPWO2022071233A1 (ja) | 2020-09-29 | 2021-09-27 | |
EP21875535.3A EP4223295A1 (en) | 2020-09-29 | 2021-09-27 | Liquid pharmaceutical composition demonstrating excellent preservation efficacy |
AU2021354445A AU2021354445A1 (en) | 2020-09-29 | 2021-09-27 | Liquid pharmaceutical composition demonstrating excellent preservation efficacy |
MX2023003603A MX2023003603A (es) | 2020-09-29 | 2021-09-27 | Composicion farmaceutica en estado liquido que exhibe excelente eficacia conservante. |
BR112023005756A BR112023005756A2 (pt) | 2020-09-29 | 2021-09-27 | Composição farmacêutica em estado líquido apresentando excelente eficácia de preservação |
CONC2023/0003536A CO2023003536A2 (es) | 2020-09-29 | 2023-03-22 | Composición farmacéutica en estado líquido que exhibe excelente eficacia conservante |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020164034 | 2020-09-29 | ||
JP2020-164034 | 2020-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022071233A1 true WO2022071233A1 (ja) | 2022-04-07 |
Family
ID=80949079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/035417 WO2022071233A1 (ja) | 2020-09-29 | 2021-09-27 | 優れた保存効力を示す液状医薬組成物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230372315A1 (ja) |
EP (1) | EP4223295A1 (ja) |
JP (1) | JPWO2022071233A1 (ja) |
KR (1) | KR20230084205A (ja) |
CN (1) | CN116472032A (ja) |
AU (1) | AU2021354445A1 (ja) |
BR (1) | BR112023005756A2 (ja) |
CA (1) | CA3194011A1 (ja) |
CL (1) | CL2023000871A1 (ja) |
CO (1) | CO2023003536A2 (ja) |
EC (1) | ECSP23020965A (ja) |
MX (1) | MX2023003603A (ja) |
PE (1) | PE20240109A1 (ja) |
TW (1) | TW202222347A (ja) |
WO (1) | WO2022071233A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06263735A (ja) | 1990-07-10 | 1994-09-20 | Ishihara Sangyo Kaisha Ltd | ジアミノトリフルオロメチルピリジン誘導体、それらの製造方法及びそれらを含有するホスホリパーゼ▲a2▼阻害剤 |
WO2001056568A1 (fr) * | 2000-01-31 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour maladies digestives, contenant des derives de diaminotrifluoromethylpyridine |
WO2010137484A1 (ja) | 2009-05-28 | 2010-12-02 | 石原産業株式会社 | ジアミノトリフルオロメチルピリジン誘導体を含有する抗ショック剤 |
JP2016040277A (ja) * | 2009-08-21 | 2016-03-24 | ターゲッティド デリバリー テクノロジーズ リミテッド | 小胞状の製剤 |
JP2016529242A (ja) * | 2013-07-31 | 2016-09-23 | シクエスサム テクノロジー ホールディングス リミテッド | ベシクル |
WO2019167979A1 (ja) | 2018-03-01 | 2019-09-06 | 石原産業株式会社 | 保存安定性に優れた医薬組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4848092B2 (ja) | 2000-02-01 | 2011-12-28 | 石原産業株式会社 | ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤 |
AU2001228862A1 (en) | 2000-02-01 | 2001-08-14 | Ishihara Sangyo Kaisha Ltd. | Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives |
-
2021
- 2021-09-27 PE PE2023001208A patent/PE20240109A1/es unknown
- 2021-09-27 MX MX2023003603A patent/MX2023003603A/es unknown
- 2021-09-27 BR BR112023005756A patent/BR112023005756A2/pt unknown
- 2021-09-27 JP JP2022553959A patent/JPWO2022071233A1/ja active Pending
- 2021-09-27 EP EP21875535.3A patent/EP4223295A1/en active Pending
- 2021-09-27 CA CA3194011A patent/CA3194011A1/en active Pending
- 2021-09-27 US US18/246,775 patent/US20230372315A1/en active Pending
- 2021-09-27 KR KR1020237014639A patent/KR20230084205A/ko unknown
- 2021-09-27 CN CN202180066887.2A patent/CN116472032A/zh active Pending
- 2021-09-27 WO PCT/JP2021/035417 patent/WO2022071233A1/ja active Application Filing
- 2021-09-27 AU AU2021354445A patent/AU2021354445A1/en active Pending
- 2021-09-29 TW TW110136251A patent/TW202222347A/zh unknown
-
2023
- 2023-03-22 EC ECSENADI202320965A patent/ECSP23020965A/es unknown
- 2023-03-22 CO CONC2023/0003536A patent/CO2023003536A2/es unknown
- 2023-03-24 CL CL2023000871A patent/CL2023000871A1/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06263735A (ja) | 1990-07-10 | 1994-09-20 | Ishihara Sangyo Kaisha Ltd | ジアミノトリフルオロメチルピリジン誘導体、それらの製造方法及びそれらを含有するホスホリパーゼ▲a2▼阻害剤 |
WO2001056568A1 (fr) * | 2000-01-31 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour maladies digestives, contenant des derives de diaminotrifluoromethylpyridine |
WO2010137484A1 (ja) | 2009-05-28 | 2010-12-02 | 石原産業株式会社 | ジアミノトリフルオロメチルピリジン誘導体を含有する抗ショック剤 |
JP2016040277A (ja) * | 2009-08-21 | 2016-03-24 | ターゲッティド デリバリー テクノロジーズ リミテッド | 小胞状の製剤 |
JP2016529242A (ja) * | 2013-07-31 | 2016-09-23 | シクエスサム テクノロジー ホールディングス リミテッド | ベシクル |
WO2019167979A1 (ja) | 2018-03-01 | 2019-09-06 | 石原産業株式会社 | 保存安定性に優れた医薬組成物 |
Non-Patent Citations (1)
Title |
---|
HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, 2017, pages 105 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022071233A1 (ja) | 2022-04-07 |
TW202222347A (zh) | 2022-06-16 |
AU2021354445A1 (en) | 2023-05-18 |
KR20230084205A (ko) | 2023-06-12 |
PE20240109A1 (es) | 2024-01-22 |
ECSP23020965A (es) | 2023-04-28 |
MX2023003603A (es) | 2023-04-05 |
CL2023000871A1 (es) | 2023-11-10 |
BR112023005756A2 (pt) | 2023-05-09 |
US20230372315A1 (en) | 2023-11-23 |
CO2023003536A2 (es) | 2023-05-29 |
CA3194011A1 (en) | 2022-04-07 |
CN116472032A (zh) | 2023-07-21 |
EP4223295A1 (en) | 2023-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007322334B2 (en) | Method of drug delivery for bone anabolic protein | |
ES2384451T3 (es) | Aplicación de levo-ornidazol en la preparación de un medicamento contra la infección de bacterias anaeróbicas . | |
CN109091489A (zh) | 大环内酯类抗生素的肠胃外制剂 | |
JP7229999B2 (ja) | ダプトマイシン製剤 | |
KR20040085196A (ko) | 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법 | |
JP2016132669A (ja) | 関節を治療するための組成物及び方法 | |
JP5931449B2 (ja) | 医薬組成物及びその製造方法 | |
TW201109040A (en) | Oral suspension comprising telmisartan | |
Gillett et al. | 32 Koala | |
Castro-Hermida et al. | Treatment with β-cyclodextrin of natural Cryptosporidium parvum infections in lambs under field conditions | |
WO2022071233A1 (ja) | 優れた保存効力を示す液状医薬組成物 | |
JP7254101B2 (ja) | 複数回使用のトラセミド組成物 | |
JP3947796B2 (ja) | メニエール病治療薬 | |
KR20140019728A (ko) | 알레르겐 함유 시트 형상 제제 및 그 제조 방법 | |
US6777448B2 (en) | Veterinary compositions for the treatment of parasitic diseases | |
KR20200008890A (ko) | 시알릴락토오스 또는 이의 유도체를 유효성분으로 함유하는 면역세포의 증식 억제용 조성물 | |
JP5322649B2 (ja) | セフキノム組成物およびその使用方法 | |
US20200330441A1 (en) | Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and methods for using same | |
JP4167283B2 (ja) | 甘味料 | |
AU2016210773B2 (en) | An anti-parasitic formulation and a method for treating parasitic infestations in an animal | |
RU2715906C2 (ru) | Применение органического экстракта цитрусовых с высокой противомикробной активностью и ксилита в качестве системы консервантов в жидкостях, эмульсиях, суспензиях, кремах и антацидах | |
RU2762088C1 (ru) | Способ лечения мастита у коров | |
JP7273257B1 (ja) | 医薬組成物 | |
US20220409651A1 (en) | Anti-fungal compositions and methods for using same | |
JP5952634B2 (ja) | 医薬組成物およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21875535 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3194011 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022553959 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180066887.2 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023005756 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237014639 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023110052 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021875535 Country of ref document: EP Effective date: 20230502 |
|
ENP | Entry into the national phase |
Ref document number: 112023005756 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230328 |
|
ENP | Entry into the national phase |
Ref document number: 2021354445 Country of ref document: AU Date of ref document: 20210927 Kind code of ref document: A |